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Objective: To assess the quality of the first batch of Chinese evidence-based clinical practice guidelines (CPGs) in 
Traditional Chinese Medicine (TCM) using the Appraisal of Guidelines for Research and Evaluation (AGREE) 
instrument.  
Methods: Evidence-based CPGs in TCM supported by the World Health Organization Western Pacific Regional 
Office (WHO/WPRO) and whose development was organized by the China Academy of Chinese Medical Sciences
were identified and manually retrieved. CPGs were assessed using the AGREE instrument, and the data in each 
CPG were analyzed in terms of the six domains in the AGREE instrument: scope and purpose, stakeholder 
involvement, rigor of development, clarity and presentation, applicability, and editorial independence.  
Results: Twenty-eight CPGs were identified, of which 26 were included in the study. The AGREE instrument rated 
the 26 CPGs in terms of the six domains. The assessment results showed the following average scores: for editorial 
independence, 84.16%; for rigor of development, 80.95%; for scope and purpose, 79.96%; for clarity and 
presentation, 70.88%; for stakeholder involvement, 61.28%; for applicability, the average score was only 27.09%. 
In summary, nine CPGs were rated as “strongly recommended”, six as “recommended with provision or 
alternation”, and 11 as “unsure”.  
Conclusion: Most of the first batch of Chinese evidence-based CPGs in TCM had significant shortcomings in 
applicability. It is suggested that special attention be paid to enhancing the quality of applicability when developing 
evidence-based CPGs in TCM.  
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quality assessment 
Clinical practice guidelines (CPGs) are systematically 
developed to assist practitioners and patients in making 
decisions about the appropriate health care in specific 
clinical circumstances.1 CPGs in Traditional Chinese 
Medicine (TCM) are basic technical standards and are 
helpful in clinical practice. CPGs in TCM have been 
increasingly used in medical decision-making, guiding 
junior TCM practitioners and biomedical doctors willing 
to practice TCM. However, the potential benefits of the 
guidelines are only as good as the quality of the 
guidelines themselves:2 only good guidelines have the 
potential to improve clinical practice.3
Consensus-based CPGs in TCM have been developed for 
many diseases; however, their quality varies greatly, and 
some CPGs do not achieve an acceptable standard.4 In 
2006, under the support of the World Health 
Organization Western Pacific Regional Office 
(WHO/WPRO), multidiscipline panels were convened 
by the China Academy of Chinese Medical Sciences 
(CACMS) to develop the first batch of evidence-based 
CPGs in TCM in China, though no quality evaluation has 
thus far been conducted. Before applying evidence-based 
CPGs in TCM, the first step is to determine their quality. 
This paper is aimed at assessing the quality of 
evidence-based CPGs in TCM. 
METHODS 
The first batch of evidence-based CPGs in TCM were 
published  in TCM journals in China;5,6 they were 
identified and manually retrieved. The evidence-based 
CPGs in TCM were assessed using the Appraisal of 
Guidelines for Research and Evaluation (AGREE) 
instrument. The AGREE instrument was developed by a 
group of researchers from 13 nations in 1998 and has 
been used in some countries to assess CPGs.7-11 The 
AGREE instrument consists of 23 key items organized in 
six domains. The six domains are scope and purpose, 
stakeholder involvement, rigor of development, clarity 
and presentation, applicability, and editorial 
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independence. Each domain is intended to capture a 
separate dimension of guideline quality. Taking each 
appraisal criterion into account, an overall assessment of 
CPGs should be made by at least two appraisers. The 
overall assessment contains a series of options: “Strongly 
recommended,” “Recommended with provisions or 
alterations,” “Not recommended,” and “Unsure”.12
The data of each CPG were gathered and then analyzed 
in terms of the six domains of the AGREE instrument. 
After completing the AGREE assessment, two appraisers 
reached consensus on the overall recommendation for 
each CPG. 
RESULTS 
Twenty-eight EB CPGs in TCM were identified, of 
which 26 met the inclusion criteria. The 26 diseases were 
as follows: diabetes, chronic obstructive pulmonary 
disease, IgA nephropathy, acquired immunodeficiency 
syndrome, obesity, common cold, hypertension, coronary 
heart disease (angina pectoris), age-related macular 
degeneration, aplastic anemia, rheumatoid arthritis, 
chronic pelvitis, chronic gastritis, chronic hepatitis B, 
cerebral infarction, migraine, chronic prostatitis, Barton 
fracture, cervical spondylotic radiculopathy, insomnia, 
atopic dermatitis, pediatric pneumonia, vascular 
dementia, psoriasis vulgaris, depression, and primary 
osteoporosis. The analysis results of the quality of 
evidence-based CPGs in TCM are shown in Table 1-1, 
1-2, and 1-3. 
Table 1-1. Six evidenced-based CPGs in TCM were evaluated using the AGREE instrument (all published in Chinese) 
Notes: Nian Ling Xiang Guan Xing Huang Ban Bian Xing Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional 
Chinese Medicine for Age-Related Macular Degeneration (Chin);6 Zai Sheng Zhang Ai Xing Pin Xue Zhong Yi Lin Chuang Shi Jian Zhi 
Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Aplastic Anemia (Chin); 6 Lei Feng Shi Xing Guan Jie Yan Zhong Yi 
Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Rheumatoid Arthritis (Chin);5 Man Xing Pen 
Qiang Yan Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Chronic Pelvitis (Chin);6
Man Xing Wei Yan Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Chronic 
Gastritis (Chin);5 Nao Geng Si Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for 
Cerebral Infarction (Chin).5














Nian Ling Xiang 
Guan Xing Huang 
Ban Bian Xing 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan 6
WHO/WPRO CACMS 77.8% 77.8% 66.7% 63.5% 51.9% 88.9% 
Zai Sheng Zhang 
Ai Xing Pin Xue 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan 6
WHO/WPRO CACMS 87.9% 83.3% 87.3% 75% 33.3% 94% 
Lei Feng Shi 
Xing Guan Jie 
Yan Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan 5
WHO/WPRO CACMS 83.3% 45.8% 91.7% 77.4% 0.0% 100% 
Man Xing Pen 
Qiang Yan Zhong 
Yi Lin Chuang 
Shi Jian Zhi Nan 6
WHO/WPRO CACMS 81.5% 63.0% 77.8% 65.1% 25.9% 77.8% 
Man Xing Wei 
Yan Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan 5
WHO/WPRO CACMS 74.1% 50.0% 80.6% 66.7% 0.0% 83.3% 
Nao Geng Si 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan 5
WHO/WPRO CACMS 92% 88% 86% 81% 69% 100% 
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Table 1-2. Ten evidenced-based CPGs in TCM were evaluated using the AGREE instrument (all published in Chinese) 
Notes: 2 Xing Tang Niao Bing Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Type 
2 Diabetes (Chin);5 Man Xing Zu Sai Xing Fei Ji Bing Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional 
Chinese Medicine for Chronic Obstructive Pulmonary Disease (Chin);5 IgA Shen Bing Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical 
Practice Guideline of Traditional Chinese Medicine for IgA Nephropathy (Chin));5 Huo De Xing Mian Yi Que Xian Zong He Zheng: Clinical 
Practice Guideline of Traditional Chinese Medicine for Acquired Immunodeficiency Syndrome (Chin);5 Dan Chun Xing Fei Pang Zhong Yi 
Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Obesity (Chin);5 Gan Mao Zhong Yi Lin 
Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for the Common Cold (Chin);5 Gao Xue Ya Bing 
Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Hypertension (Chin);5 Man Xing 
Wen Ding Xing Xin Jiao Tong Zhong Yi Lin Chuang;Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for 
Coronary Heart Disease (angina pectoris) (Chin);5 Pian Tou Tong Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of 
Traditional Chinese Medicine for Migraine (Chin).5 Man Xing Yi Xing Gan Yan Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice 
Guideline of Traditional Chinese Medicine for Chronic Hepatitis B (Chin).5

















2 Xing Tang Niao 
Bing Zhong Yi 
Lin Chuang Shi 
Jian Zhi Nan5 
WHO/WPRO CACMS 84.1% 56.4% 81.3% 67.8% 0.0% 82.7% 
Man Xing Zu Sai 
Xing Fei Ji Bing 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan5 
WHO/WPRO CACMS 66.6% 56.2% 60.4% 64.3% 0.0% 70.8% 
IgA Shen Bing 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan5
WHO/WPRO CACMS 66.7% 44.4% 75.0% 63.5% 0.0% 95.0% 
Huo De Xing 
Mian Yi Que 
Xian Zong He 
Zheng5
WHO/WPRO CACMS 63.3% 47.2% 63.8% 55.5% 0.0% 83.3% 
Dan Chun Xing 
Fei Pang Zhong 
Yi Lin Chuang 
Shi Jian Zhi Nan5
WHO/WPRO CACMS 74.1% 50.0% 88.9% 69.8% 66.7% 83.3% 
Gan Mao Zhong 
Yi Lin Chuang 
Shi Jian Zhi Nan5
WHO/WPRO CACMS 81.5% 69.4% 83.3% 77.8% 51.9% 77.8% 
Gao Xue Ya Bing 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan 5
WHO/WPRO CACMS 93% 67% 79% 83% 52% 94% 
Man Xing Wen 
Ding Xing Xin 
Jiao Tong Zhong 
Yi Lin Chuang 
Shi Jian Zhi Nan5
WHO/WPRO CACMS 83.33% 68.75% 64.58% 60.71% 55.56% 87.50% 
Pian Tou Tong 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan5
WHO/WPRO CACMS 94.4% 66.0% 88.0% 70.8% 66.6% 100% 
Man Xing Yi 
Xing Gan Yan 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan5
WHO/WPRO CACMS 92.59% 66.67% 87.18% 94.67% 25.93% 100% 
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Table 1-3. Six evidenced-based CPGs in TCM were evaluated using the AGREE instrument (all published in Chinese) 
Notes: Rao Gu Yuan Duan Gu Zhe Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for 
Barton Fracture (Chin;6 Shen Jing Gen Xing Jing Zhui Bing Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of 
Traditional Chinese Medicine for Cervical Spondylotic Radiculopathy (Chin);6 Shi Mian Zheng Zhong Yi Lin Chuang Shi Jian Zhi Nan: 
Clinical Practice Guideline of Traditional Chinese Medicine for Insomnia (Chin);5 Te Ying Xing Pi Yan Zhong Yi Lin Chuang Shi Jian Zhi 
Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Atopic Dermatitis (Chin);5 Xiao Er Fei Yan Zhong Yi Lin Chuang Shi 
Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Pediatric Pneumonia (Chin);6 Xue Guan Xing Chi Dai Zhong 
Yi Lin Chuang Shi Jian Zhi; Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Vascular Dementia (Chin);5 Xun Chang 
Xing Yin Xie Bing Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for Psoriasis 
Vulgaris (Chin);6 Yi Yu Zheng Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of Traditional Chinese Medicine for 
Depression (Chin);5 Yuan Fa Xing Gu Zhi Shu Song Zheng Zhong Yi Lin Chuang Shi Jian Zhi Nan: Clinical Practice Guideline of 
Traditional Chinese Medicine for Primary Osteoporosis (Chin);5 Man Xing Qian Lie Xian Yan Zhong Yi Lin Chuang Shi Jian Zhi Nan: 
Clinical Practice Guideline of Traditional Chinese Medicine for Chronic Prostatitis (Chin).6

















Rao Gu Yuan 
Duan Gu Zhe 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan6
WHO/WPRO CACMS 85.2% 69.4% 91.7% 87.3% 59.3% 100% 
Shen Jing Gen 
Xing Jing Zhui 
Bing Zhong Yi 
Lin Chuang Shi 
Jian Zhi Nan6
WHO/WPRO CACMS 74.1% 50.0% 80.6% 66.7% 0.0% 83.3% 
Shi Mian Zheng 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan 5
WHO/WPRO CACMS 88.9% 63.9% 88.9% 73.0% 45.80% 100% 
Te Ying Xing Pi 
Yan Zhong Yi 
Lin Chuang Shi 
Jian Zhi Nan 5
WHO/WPRO CACMS 74.1% 50.0% 80.6% 66.7% 0.0% 83.3% 
Xiao Er Fei Yan 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan 6
WHO/WPRO CACMS 66.7% 50.0% 79.4% 52.8% 0.0% 77.8% 
Xue Guan Xing 
Chi Dai Zhong 
Yi Lin Chuang 
Shi Jian Zhi 
Nan5
WHO/WPRO CACMS 74.1% 50.0% 80.6% 66.7% 0.0% 83.3% 
Xun Chang Xing 
Yin Xie Bing 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan6
WHO/WPRO CACMS 83.3% 60.4% 77.1% 79.7% 25.0% 87.5% 
Yi Yu Zheng 
Zhong Yi Lin  
Chuang Shi Jian 
Zhi Nan5
WHO/WPRO CACMS 77.8% 61.1% 91.67% 74.6% 18.5% 88.9% 
Yuan Fa Xing 
Gu Zhi Shu 
Song Zheng 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan5
WHO/WPRO CACMS 92% 83% 92% 83% 57% 83% 
Man Xing Qian 
Lie Xian Yan 
Zhong Yi Lin 
Chuang Shi Jian 
Zhi Nan6
WHO/WPRO CACMS 66.6% 55.5% 80.5% 55.9% 0.0% 83.3% 
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Scope and Purpose 
The majority of CPGs presented their scope and purpose 
well, scoring over 60% in this domain. Among the 26 
CPGs, five scored 60%–70%, seven scored 70%–80%, 
nine 80%–90%, and five over 90%. The average domain 
score was 79.96%. 
Stakeholder Involvement 
Target users were not defined well in most guidelines, 
and the majority of CPG development groups did not 
involve the patient’s perspective. Among the 26 CPGs, 
12 scored under 60%, 10 scored between 60% and 70%, 
one between 70% and 80%, three between 80% and 90%;
the average score was 61.28%. 
Rigor of Development 
Nearly all the CPGs described the search methods for 
evidence in detail, and the levels of evidence and grading 
of recommendation were reported clearly: in this way, 
the link between recommendation and supporting 
evidence was explicit. However, the balance between 
benefits and side effects or risks was rarely considered. 
All CPGs underwent external expert review before being 
published, and the CPG updating procedure was 
considered. Overall, the average score for this domain 
was 80.95%; four CPGs scored over 90%, 13 between 
80% and 90%, five between 70% and 80%, and four 
between 60% and 70%. 
Clarity and Presentation 
The key recommendations of most CPGs were easy to 
identify, but the clarity of the recommendations needs to 
be improved. Some CPGs indicated no tools for 
application. Three CPGs scored under 30%, 11 between 
60% and 70%, seven between 70% and 80%, four 
between 80% and 90%, and one over 90%; the average 
domain score was 70.88%. 
Applicability 
Few CPGs clearly defined potential cost implications or 
provided any detail of barriers posed by other 
organizations in applying the CPGs, though they did 
present performance-monitoring indicators. The 
applicability score was the lowest one among the six 
domains: 11 CPGs scored zero, and 15 between 60% and 
70%; the average score was 27.09%. 
Editorial Independence 
Most CPGs defined editorial independence or conflicts 
of interest among the guideline authors. Four CPGs 
scored between 70% and 80%, 13 between 80% and 90%, 
and nine over 90%; the average score was 84.16%. 
Overall Assessment 
On the whole, nine of twenty-six CPGs were rated as 
strongly recommended, six CPGs were rated as 
recommended with provisions or alterations, and 11 
CPGs were rated as unsure. 
DISCUSSION 
The expert committee and the multidisciplinary panels 
were convened by CACMS in 2006. Under the guidance 
of the expert committee, the multidisciplinary panels 
developed the first batch of evidence-based CPGs in 
TCM in China from 2006 to 2011. Before developing the 
CPGs, the expert committee stipulated that all members 
of the multidisciplinary panels be well trained, and it 
provided a common structure and techniques relating to 
CPGs for the multidisciplinary panels. The development 
procedure adhered to that of a Scottish Intercollegiate 
guideline network, and assessment of the quality levels13
and recommendation grading14 of the published evidence 
was conducted. Where the published evidence was 
inadequate, expert consensus was reached. After drafting 
of a CPG was completed, it was reviewed by external 
experts; then, three or four appraisers without personal 
conflicts of interest were selected to evaluate the CPG 
independently using the AGREE instrument. 
Some countries have developed their own CPG appraisal 
instruments. A systematic review of 24 different 
appraisal tools and some studies has shown that the 
AGREE instrument is an acceptable standard for 
guideline evaluation.16-18 The expert committee 
recommended that the AGREE instrument be used as a 
tool to assess the quality of the first batch of 
evidence-based CPGs in TCM. 
The AGREE assessment showed that the quality of the 
evidence-based CPGs in TCM was higher than that of 
some other CPGs in the literature reviewed.7,8;10,11 The 
average scores for five domains—scope and purpose, 
stakeholder involvement, rigor of development, clarity 
and presentation, and editorial independence—were all 
over 50%, though the average score for applicability was 
only 27.09%. The reason for the low average score in 
applicability was that 11 guidelines scored zero in this 
domain. Applicability contains items relating to 
organizational barriers, cost/resource implications for 
recommendations, and key review criteria for monitoring 
and/or audit purposes. Nearly half of the CPGs gave no 
consideration of organizational barriers in guideline 
implementation; instead, they supplied monitoring 
criteria to assess the guideline’s impact. This may partly 
be because the expense of traditional and herbal drugs is 
low, and decoctions consisting of a number of herbs are 
popularly used in clinical practice. It is difficult to give a 
clear definition about potential cost implications or 
details of the administrative impact of applying CPGs. 
The present study has some limitations. This paper 
focused only on evidence-based CPGs in TCM, and it 
did not include other type of guidelines. For example, the 
consensus-based guidelines that constitute a high 
proportion of CPGs in TCM4 were not included. In 
addition, the sample size of the CPGs was relatively 
small. Despite these limitations, this study clearly 
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showed the overall quality of the first batch of 
evidence-based CPGs in TCM in China. 
In conclusion, the majority of evidence-based CPGs in 
TCM have significant shortcomings in applicability. This 
suggests that special attention should be paid to 
enhancing the quality of applicability when developing 
evidence-based CPGs in TCM. 
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